Company intelligence / Profile preview
Lyntonix
Taipei, Taiwanlyntonix.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Lyntonix is developing first-in-class oral therapeutics targeting abdominal/visceral pain in irritable bowel syndrome. Their lead candidate has demonstrated potent and long-lasting analgesic effects with a high safety index in preclinical models. The company seeks co-development partners and aims to out-license after early clinical proof-of-concept studies expected to complete by or after 2027. No clinical results are available yet as programs are preclinical.[1][3]
- Therapeutic areas
- GastroenterologyNeurology
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Seeking co-development partners but none disclosed yet.
Beyond the preview
Go deeper on Lyntonix.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Lyntonix.